|
|
 |
 |
Selected indications and products:
|
 |
|
 |
|
|
|
 |
Scheduled omnibus studies:
|
|
|
|
|
|
|
| TPCASM (Target Profile Conjoint Analysis) |
|
|
Bioscience Market Research (BSMR) promotes the early use of conjoint analysis. In a conjoint analysis, participating physicians (or other health care professionals or patients) are asked to choose between alternative product profiles. There are various ways to present drug profiles; today they are usually presented on a computer screen. The physician is asked which drug she would prescribe, simulating a real life choice situation. Once the physician has made her choice, she sees the next set of product profiles. Any profile is a set of attributes related to efficacy, safety, tolerability, formulation, convenience, frequency of administration, brand name and price. Those attributes are expressed at different levels, e.g., therapy price may be $100, $150 or $200. A sophisticated mathematical algorithm allows BSMR to extract valuable information from the choices made. For example, for new drugs conjoint analyses provide important information about the optimal launch price and potential market share. Therefore, the likelihood of success for any compound can be tested long before it would reach the market. This can help prevent developing a product based on a product profile that would find little acceptance in the market.
Since conjoint analyses are quite expensive they are usually not conducted before Phase III clinical trials. However, at this advanced stage it is very difficult to correct disadvantageous features of a particular product. Therefore, conjoint analyses should be conducted much earlier. In fact, initial product profile testing should ideally occur already at the preclinical level and should lead to a product optimization effort jointly driven by marketing and R&D.
Initial conjoint analyses should, however, not replace the more detailed studies preceeding product launch. Instead, early conjoint analyses are used to direct R&D efforts towards developing a product that will most likely be successful in the market.
Bioscience Market Research offers quality conjoint analyses at affordable prices to promote early use of this methodology. By using the conjoint simulator that is delivered with the model clients can test a product's utility and determine whether a product is likely to be a market success or failure. If market acceptance is below expectations, clients can modulate the profile to determine which changes have to be implemented to increase market demand.
 Epidemiology and patient flow
Primary and secondary market research
Analysis of competing drugs
TPCASM (Target Profile Conjoint Analysis)
DMMSM (Dynamic Market Modeling) |
 |
|
